Skip to main content
CGEM
NASDAQ Life Sciences

Cullinan Therapeutics Reports Positive Initial Phase 1 Data for CLN-978 in Autoimmune Diseases

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$14.87
Mkt Cap
$913.881M
52W Low
$5.68
52W High
$16.74
52W Position info
162% above low
Off High info
11% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

CGEM has more than doubled off its 52-week low of $5.68 on elevated volume (2.2× avg).

Summary

Cullinan Therapeutics announced positive initial Phase 1 clinical data for its drug candidate CLN-978 in patients with treatment-refractory rheumatoid arthritis and systemic lupus erythematosus, showing robust B cell depletion and promising efficacy.


Key Events · Product Development and Regulatory · CGEM

  • Positive Phase 1 Data for CLN-978

    Initial clinical data from the Phase 1 OUTRACE program for CLN-978 showed robust B cell depletion and promising clinical efficacy in patients with treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

  • Favorable Safety Profile

    CLN-978 was well tolerated and demonstrated a favorable safety profile in both RA and SLE patients, with dose escalation continuing in these studies.

  • Upcoming EULAR Presentation

    The company will present updated data, including additional patients, at the European Alliance of Associations for Rheumatology (EULAR) Congress in June 2026.

  • Strategic Importance for Financing

    This positive pipeline development is significant for the company's ability to secure future financing, especially given its recently reported reduced cash runway.


Analysis · CGEM · Life Sciences

This 8-K details promising initial Phase 1 clinical data for CLN-978 in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The drug demonstrated robust B cell depletion and early signs of clinical efficacy with a favorable safety profile. This positive pipeline development is critical for the company, especially following recent disclosures of a reduced cash runway, as it strengthens the case for future financing and validates its drug development strategy.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CGEM was trading at $14.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $913.9M. The 52-week trading range was $5.68 to $16.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $11.51 info
Change: -$1.84 (-14%) info
Market Cap: $727.852M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $11.51 info
Change: -$3.04 (-21%) info
Market Cap: $727.852M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $11.51 info
Change: -$5.37 (-32%) info
Market Cap: $727.852M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $11.51 info
Change: -$9.09 (-44%) info
Market Cap: $727.852M info
CGEM
Sep 13, 2026, 7:15 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.11
Real-time Price: $11.51 info
Change: -$9.60 (-45%) info
Market Cap: $727.852M info